GEN Exclusives

More »

GEN News Highlights

Back to Item »

Exelixis and Boehringer Ingelheim Ink $354M Autoimmune Disease Partnership

Exelixis will receive $15 million up front, and focus is on S1P1 receptor agonists.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?